Changchun High-Tech Industry(000661.SZ) subsidiary Fuxinqibaixi monoclonal antibody injection has been approved for listing in the domestic market.
Changchun High-tech (000661.SZ) announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jinsai Pharmaceutical"), recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration. The application for domestic production and listing approval of Jinsai Pharmaceutical's Fuxin Qibai monoclonal antibody injection has been approved.
Changchun High-Tech Industry (000661.SZ) has announced that its holding subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), recently received the "Drug Registration Certificate" issued by the National Medical Products Administration. The domestic production drug registration and listing application for Jinxin Qibai monoclonal antibody injection manufactured by Jinsai Pharmaceutical has been approved.
Jinxin Qibai monoclonal antibody is a new type of fully human anti-IL-1 monoclonal antibody drug developed by Jinsai Pharmaceutical. It is classified as a level 1 new drug for therapeutic biological products, specifically binding to human IL-1 to block the production of inflammatory mediators induced by IL-1. It is used for adult patients with acute gouty arthritis.
Related Articles
Industrial: Hong Kong stock Internet is expected to become an important direction for the diffusion of AI trends.
China Tower (00788): Li Zhangting resigns as supervisor
On May 6th, BEKE-W(02423) spent approximately $2 million to repurchase 321,000 shares.
Industrial: Hong Kong stock Internet is expected to become an important direction for the diffusion of AI trends.
China Tower (00788): Li Zhangting resigns as supervisor
On May 6th, BEKE-W(02423) spent approximately $2 million to repurchase 321,000 shares.
